Calton & Associates, Inc. Cellectis S.A. Transaction History
Calton & Associates, Inc.
- $542 Million
- Q2 2025
A detailed history of Calton & Associates, Inc. transactions in Cellectis S.A. stock. As of the latest transaction made, Calton & Associates, Inc. holds 20 shares of CLLS stock, worth $72. This represents 0.0% of its overall portfolio holdings.
Number of Shares
20Holding current value
$72% of portfolio
0.0%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding CLLS
# of Institutions
27Shares Held
13.2MCall Options Held
0Put Options Held
0-
Long Focus Capital Management, LLC San Juan, PR4.72MShares$17.1 Million0.33% of portfolio
-
B Group, Inc. Dallas, TX3.26MShares$11.8 Million3.82% of portfolio
-
Ubs Asset Management Americas Inc Chicago, IL3.18MShares$11.5 Million0.0% of portfolio
-
Credit Suisse Ag Zurich, V81.44MShares$5.22 Million0.0% of portfolio
-
Macquarie Group LTD Australia, C3227KShares$823,5560.0% of portfolio
About Cellectis S.A.
- Ticker CLLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,510,800
- Market Cap $165M
- Description
- Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...